Bayer Group Is Optimistic about Sales and Earnings Growth
The Bayer Group sees continuing good business prospects for the medium term. “We're optimistic for all of our subgroups and see continuing potential for further sales and earnings growth in the medium term,” Bayer CEO Dr. Marijn Dekkers said on Wednesday at the “Meet Management” investor conference in Leverkusen, Germany. Sales and margin at Bayer HealthCare are planned to increase through 2016, mainly thanks to the recently launched pharmaceutical products. Over the same period, Bayer CropScience also intends to substantially grow its business, maintaining its margin at an industry-leading level. In an improved market environment, Bayer MaterialScience expects good sales and earnings momentum. These prospects are based on average exchange rates for the fourth quarter of 2013, including a rate of USD 1.36 to the euro.
“At MaterialScience, we're cautiously optimistic for the future despite the difficult market environment we encountered last year,” said Dekkers. The growth expected in the coming years and the resulting higher capacity utilization should ease the pressure on prices in the business with high-tech polymer materials. The ongoing efficiency measures are designed to add to the resulting improvement in profitability. The subgroup aims to earn its cost of capital again by 2016 at the latest.
Covestro Deutschland AG
Would you like to subscribe to our Newsletters on plastics technology and profit from the latest information?
Looking for a new challenge? Check out our jobs market!
Patents encourage innovation: Stay on the ball with the latest innovations in the plastics industry in our patents section.